The Spinal Muscular Atrophy (SMA) Biomarkers Study is the first trial within the NeuroNEXT Network to enroll a participant
NeuroNEXT Trial of SMA Biomarkers Enrolls First Participant
The Spinal Muscular Atrophy (SMA) Biomarkers in the Immediate Postnatal Period of Development Study seeks to identify prognostic and surrogate biomarkers of disease progression that will facilitate the execution of therapeutic SMA clinical trials in infants.
In December 2012, the SMA study enrolled its first participant, the first of any Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT, Trials.
See the announcement.
U.S. News & World Report ranks Mass General #2 in the nation and #1 in New England based on our quality of care, patient safety and reputation in 16 clinical specialties.
Search the archive for previously published news articles, press releases and publications.
Departments and Centers at Mass General have a reputation for excellence in patient care. View a list of all departments.